From Bench to Bedside： Targeting Epigenetics for Cancer Therapy

The initiation and progression of cancer not only involves genetic abnormalities, but also epigenetic alterations, such as DNA methylation and histone modifications. Epigenetics refers to the heritable changes that do not involve any structural changes in the target gene, i.e., DNA sequence and prot...

Full description

Saved in:
Bibliographic Details
Published inCancer biology & medicine Vol. 8; no. 4; pp. 191 - 201
Main Authors Li, Gui-deng, Fang, Jin-xu
Format Journal Article
LanguageEnglish
Published Heidelberg Tianjin Medical University Cancer Institute and Hospital 01.12.2011
Chinese Anti-Cancer Association (CACA), Cancer Biology & Medicine
Institute for Immunology, School of Medicine, University of California, Irvine, CA 92697-4120, USA%Department of Chemical Engineering and Materials Science, Viterbi School of Engineering,University of Southern California, Los Angeles,California 90089, USA
China Anti-Cancer Association
Subjects
Amino acid sequence
Cancer
cancer epigenetics
Cancer therapies
Deoxyribonucleic acid
DNA
DNA methylation
DNA甲基化
Drug discovery
epigenetic drugs
Epigenetics
histone modifications
Medicine
Medicine & Public Health
Nucleotide sequence
Oncology
临床
实验室
状态恢复
癌症
组蛋白去乙酰化酶
表观遗传学
靶向治疗
DNA methylation
epigenetic drugs
cancer epigenetics
histone modifications
Online AccessGet full text

Cover

More Information
Summary:The initiation and progression of cancer not only involves genetic abnormalities, but also epigenetic alterations, such as DNA methylation and histone modifications. Epigenetics refers to the heritable changes that do not involve any structural changes in the target gene, i.e., DNA sequence and protein sequence. Thus, these epigenetic aberrations are potentially reversible, allowing the malignant cells to revert to a state with more normal characteristics. The use of epigenetics is emerging as an effective and promising approach to treat cancer. Epigenetic drugs, which target two well- known epigenetic pathways, namely, DNA methyltransferases and histone deacetylases, are already being applied for the cancer treatment. In the current study, an overview regarding the under-standing of epigenetic alterations in the development of cancer and the current state of epigenetic drug discovery is provided.
Bibliography:Gui-deng LI, Jin-xu FANG（1 Institute for Immunology, School of Medicine, University of California, Irvine, CA 92697-4120, USA;2 Department of Chemical Engineering and Materials Science, Viterbi School of Engineering, University of Southern California, Los Angeles, California 90089, USA）
cancer epigenetics, DNA methylation, histonemodifications, epigenetic drugs.
12-1404/R
The initiation and progression of cancer not only involves genetic abnormalities, but also epigenetic alterations, such as DNA methylation and histone modifications. Epigenetics refers to the heritable changes that do not involve any structural changes in the target gene, i.e., DNA sequence and protein sequence. Thus, these epigenetic aberrations are potentially reversible, allowing the malignant cells to revert to a state with more normal characteristics. The use of epigenetics is emerging as an effective and promising approach to treat cancer. Epigenetic drugs, which target two well- known epigenetic pathways, namely, DNA methyltransferases and histone deacetylases, are already being applied for the cancer treatment. In the current study, an overview regarding the under-standing of epigenetic alterations in the development of cancer and the current state of epigenetic drug discovery is provided.
ISSN:1674-5361
2095-3941
1868-324X
DOI:10.1007/s11805-011-0580-x